When men search online for answers about low energy, reduced libido, or declining muscle mass, they are increasingly landing on commercial testosterone clinic websites — and a significant proportion of those sites are telling them things that clinical guidelines explicitly do not support. In an era when testosterone prescriptions have risen up to twelvefold globally in two decades, understanding what prospective patients actually read online has direct public health consequences.
A systematic content analysis of 1,138 websites across four languages — English, Arabic, Hindi, and Spanish — and multiple geographic regions identified 253 sites actively offering testosterone prescriptions. Researchers coded each site against international hypogonadism guidelines and found widespread divergence. Approximately 24% of sites promoted non-testosterone androgens or secretagogues such as gonadotrophins as first-line treatments for symptomatic low testosterone, a practice not endorsed in standard protocols. More strikingly, roughly one in five sites (20.6%) claimed testosterone therapy reduces cardiovascular risk — a claim that contradicts decades of contested but ultimately cautionary cardiovascular safety data. Other non-guideline practices included microdosing claims (11.9%), prescribing for men with normal serum testosterone above 12 nmol/L (9.9%), and promotion of testosterone as an anti-aging intervention (9.9%). US and Canadian clinics were disproportionately responsible for these inaccuracies.
This finding sits within a broader pattern of direct-to-consumer testosterone marketing outpacing regulatory enforcement, particularly in jurisdictions where online prescribing operates in grey zones. The cardiovascular claim is especially concerning: the FDA's 2015 labeling update explicitly warned against prescribing testosterone for age-related decline, and the TRAVERSE trial — the largest cardiovascular outcomes study to date — showed non-inferiority but not benefit. Sites claiming protective cardiovascular effects are inverting the evidence. This study's multilingual, multi-regional scope is a genuine methodological strength, though the absence of site-traffic weighting means high-volume platforms and low-traffic outliers receive equal analytical weight. For health-literate adults, this research is a reminder that clinic credentialing and guideline adherence are not legible from a website's professional appearance alone.